Neurizon Therapeutics Limited (ASX:NUZ)
Australia · Delayed Price · Currency is AUD 0.0780
0.00 (0.00%)
Sep 11, 2026, 11:11 AM AEST
Neurizon Therapeutics Company Description
Neurizon Therapeutics Limited, a clinical stage biotechnology company, engages in the development of treatments for neurodegenerative diseases in Australia.
Its lead candidate is NUZ-001, a small molecule drug designed to support cellular protein homeostasis which is evaluated in Regimen I of the Phase 2/3 HEALEY ALS platform trial for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024.
Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Neurizon Therapeutics Limited
| Country | Australia |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Michael Thurn |
Contact Details
Address: 385 Bourke Street Melbourne, VIC 3000 Australia | |
| Phone | 61 3 9692 7222 |
| Website | neurizon.com |
Stock Details
| Ticker Symbol | NUZ |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000357261 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sergio Duchini | Interim Executive Chairman |
| Dan O'Connell | Chief Financial Officer |
| John Clark | Chief Operating Officer |
| Lidija Damjanovic | Head of Marketing and Corporate Affairs |
| Dr. Gary Pitt | Head of Chemistry |
| Dr. James Rixson | Head of Production |
| Dr. Herbert Brinkman | Head of Manufacturing |
| Dr. Chris Freitag M.D. | Chief Medical Advisor |
| Dr. Martin Engel | Head of Business Development |
| Stefan Ross | Company Secretary |